{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:53:47Z","timestamp":1790139227100,"version":"4.0.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.diabet.2024.101571","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:51:16Z","timestamp":1724475076000},"page":"101571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: A population-based cohort study"],"prefix":"10.1016","volume":"51","author":[{"given":"Oscar Hou In","family":"Chou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheuk To","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Shi Kai","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Ngai Chiu","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena Yan Hiu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Christopher","family":"Dee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenrick","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo Hok Him","family":"Pui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard Man Yung","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5510-1253","authenticated-orcid":false,"given":"Gary","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2024.101571_bib0001","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s11892-013-0426-4","article-title":"The growing prevalence of type 2 diabetes: increased incidence or improved survival?","volume":"13","author":"Maruthur","year":"2013","journal-title":"Curr Diabetes Rep"},{"key":"10.1016\/j.diabet.2024.101571_bib0002","series-title":"Prostate Cancer","author":"Leslie","year":"2023"},{"key":"10.1016\/j.diabet.2024.101571_bib0003","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.diabet.2024.101571_bib0004","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s10552-010-9530-9","article-title":"History of diabetes mellitus and the risk of prostate cancer: the Ohsaki Cohort Study","volume":"21","author":"Li","year":"2010","journal-title":"Canc Causes Control"},{"key":"10.1016\/j.diabet.2024.101571_bib0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/pcan.2012.40","article-title":"Type 2 diabetes and risk of prostate cancer: a meta-analysis of observational studies","volume":"16","author":"Bansal","year":"2013","journal-title":"Prostate Canc Prostatic Dis"},{"key":"10.1016\/j.diabet.2024.101571_bib0006","doi-asserted-by":"crossref","first-page":"12299","DOI":"10.1002\/cam4.5927","article-title":"Sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: a population-based study","volume":"12","author":"Chung","year":"2023","journal-title":"Canc Med"},{"key":"10.1016\/j.diabet.2024.101571_bib0007","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1186\/s12885-022-10115-3","article-title":"Metformin regulates multiple signaling pathways within castration-resistant human prostate cancer cells","volume":"22","author":"Olokpa","year":"2022","journal-title":"BMC Canc"},{"key":"10.1016\/j.diabet.2024.101571_bib0008","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1093\/annonc\/mdr037","article-title":"Metformin in prostate cancer: two for the price of one","volume":"22","author":"Clements","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.diabet.2024.101571_bib0009","doi-asserted-by":"crossref","first-page":"674","DOI":"10.6004\/jnccn.2022.7010","article-title":"Risk of new-onset prostate cancer for metformin versus sulfonylurea use in type 2 diabetes mellitus: a propensity score-matched study","volume":"20","author":"Lee","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.diabet.2024.101571_bib0010","first-page":"1","article-title":"Asian ethnicity and risk of prostate cancer in type 2 diabetes: a systematic review and meta-analysis","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Canc"},{"key":"10.1016\/j.diabet.2024.101571_bib0011","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.diabet.2024.101571_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.725465","article-title":"Sodium-glucose co-transporter 2 inhibitors may change the development of urinary tract and hematological malignancies as compared with dipeptidyl peptidase-4 inhibitors: data of the post-hoc analysis of a nationwide study","volume":"11","author":"Rokszin","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.diabet.2024.101571_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106094","article-title":"Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: a systematic review and meta-analysis","author":"Cui","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabet.2024.101571_bib0014","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4093\/dmj.2017.41.2.81","article-title":"A clinical practice guideline to guide a system approach to diabetes care in Hong Kong","volume":"41","author":"Lau","year":"2017","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.diabet.2024.101571_bib0015","article-title":"Population-based clinical studies using routinely collected data in Hong Kong, China: a systematic review of trends and established local practices","volume":"8","author":"Derek","year":"2023","journal-title":"CVIA"},{"key":"10.1016\/j.diabet.2024.101571_bib0016","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1093\/rheumatology\/keac509","article-title":"Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes","volume":"62","author":"Zhou","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.diabet.2024.101571_bib0017","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2023.7118","article-title":"Lower risks of new-onset hepatocellular carcinoma in patients with type 2 diabetes mellitus treated with SGLT2 inhibitors versus DPP4 inhibitors","volume":"22","author":"Chou","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.diabet.2024.101571_bib0018","article-title":"Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study","author":"Chou","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.diabet.2024.101571_bib0019","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000521288","article-title":"Charlson Comorbidity Index: a critical review of clinimetric properties","volume":"91","author":"Charlson","year":"2022","journal-title":"Psychother Psychosom"},{"key":"10.1016\/j.diabet.2024.101571_bib0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3109\/0886022X.2012.731970","article-title":"Comparison of abbreviated modification of diet in renal disease formula (aMDRD) and the Cockroft-Gault adjusted for body surface (aCG) equations in stable renal transplant patients and living kidney donors","volume":"35","author":"Soliman","year":"2013","journal-title":"Ren Fail"},{"key":"10.1016\/j.diabet.2024.101571_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023489","article-title":"Switching to versus addition of incretin-based drugs among patients with type 2 diabetes taking sodium-glucose cotransporter-2 inhibitors","volume":"11","author":"Lau","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.diabet.2024.101571_bib0022","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.diabet.2024.101571_bib0023","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.diabet.2024.101571_bib0024","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/sjos.12542","article-title":"Stable inverse probability weighting estimation for longitudinal studies","volume":"48","author":"Avagyan","year":"2021","journal-title":"Scand J Statistics"},{"key":"10.1016\/j.diabet.2024.101571_bib0025","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/aja.2010.126","article-title":"Prostate cancer: an emerging threat to the health of aging men in Asia","volume":"13","author":"Zhang","year":"2011","journal-title":"Asian J Androl"},{"key":"10.1016\/j.diabet.2024.101571_bib0026","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Canc J Clin"},{"key":"10.1016\/j.diabet.2024.101571_bib0027","doi-asserted-by":"crossref","first-page":"559","DOI":"10.3390\/ijerph13060559","article-title":"Incidence and mortality risks of cancer in patients with type 2 diabetes: a retrospective study in Shanghai, China","volume":"13","author":"Gu","year":"2016","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.diabet.2024.101571_bib0028","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/dc11-1313","article-title":"Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival","volume":"35","author":"Currie","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2024.101571_bib0029","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1186\/s40064-016-3233-y","article-title":"Diabetes and mortality in patients with prostate cancer: a meta-analysis","volume":"5","author":"Lee","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.diabet.2024.101571_bib0030","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41416-020-0910-y","article-title":"The association of diabetes with risk of prostate cancer defined by clinical and molecular features","volume":"123","author":"Feng","year":"2020","journal-title":"Br J Canc"},{"key":"10.1016\/j.diabet.2024.101571_bib0031","first-page":"647","article-title":"Expression of CD26 and CXCR4 in prostate carcinoma and its relationship with clinical parameters","volume":"18","author":"Lu","year":"2013","journal-title":"J Res Med Sci"},{"key":"10.1016\/j.diabet.2024.101571_bib0032","series-title":"The SGLT2 inhibitor canagliflozin reduces androgen receptor expression and nuclear localization of beta-catenin in human prostate cancer cells","author":"Bekele","year":"2022"},{"key":"10.1016\/j.diabet.2024.101571_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106039","article-title":"Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials","volume":"175","author":"Benedetti","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabet.2024.101571_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232283","article-title":"Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)","volume":"15","author":"Nakano","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.diabet.2024.101571_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110821","article-title":"Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK\/mTOR pathway","volume":"132","author":"Zhou","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.diabet.2024.101571_bib0036","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.diabet.2024.101571_bib0037","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.molmet.2016.08.014","article-title":"The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration","volume":"5","author":"Villani","year":"2016","journal-title":"Molecular Metab"},{"key":"10.1016\/j.diabet.2024.101571_bib0038","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.diabet.2024.101571_bib0039","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/EDE.0000000000001486","article-title":"Incretin-based drugs and the incidence of prostate cancer among patients with type 2 diabetes","volume":"33","author":"Lu","year":"2022","journal-title":"Epidemiology"},{"key":"10.1016\/j.diabet.2024.101571_bib0040","doi-asserted-by":"crossref","first-page":"19057","DOI":"10.18632\/oncotarget.12137","article-title":"Sitagliptin may reduce prostate cancer risk in male patients with type 2 diabetes","volume":"8","author":"Tseng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.diabet.2024.101571_bib0041","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc17-1825","article-title":"Neoplasms reported with liraglutide or placebo in people with type 2 diabetes: results from the LEADER Randomized Trial","volume":"41","author":"Nauck","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabet.2024.101571_bib0042","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pros.24443","article-title":"Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study","volume":"83","author":"Lee","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.diabet.2024.101571_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043487","article-title":"Predicting dementia diagnosis from cognitive footprints in electronic health records: a case\u2013control study protocol","volume":"10","author":"Luo","year":"2020","journal-title":"BMJ Open"},{"key":"10.1016\/j.diabet.2024.101571_bib0044","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2147\/JAA.S405297","article-title":"Validation of diagnostic coding for asthma in an electronic health record system in Hong Kong","volume":"16","author":"Kwok","year":"2023","journal-title":"J Asthma Allergy"},{"issue":"1","key":"10.1016\/j.diabet.2024.101571_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.102168","article-title":"Healthcare Big Data in Hong Kong: Development and Implementation of Artificial Intelligence-Enhanced Predictive Models for Risk Stratification","volume":"49","author":"Tse","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.diabet.2024.101571_bib0046","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.diabet.2024.101571_bib0047","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1002\/ehf2.12929","article-title":"Multi-modality machine learning approach for risk stratification in heart failure with left ventricular ejection fraction <\/= 45","volume":"7","author":"Tse","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.diabet.2024.101571_bib0048","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000443527","article-title":"The impact of obstructive sleep apnea and tobacco smoking on endothelial function","volume":"91","author":"Lui","year":"2016","journal-title":"Respiration"},{"key":"10.1016\/j.diabet.2024.101571_bib0049","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1440-1843.2007.01084.x","article-title":"Reference values of diffusing capacity of non-smoking Chinese in Hong Kong","volume":"12","author":"Ip","year":"2007","journal-title":"Respirology"},{"key":"10.1016\/j.diabet.2024.101571_bib0050","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.sleep.2013.04.023","article-title":"Linguistic and psychometric validation of the Chinese version of the self-efficacy measures for sleep apnea questionnaire","volume":"14","author":"Lai","year":"2013","journal-title":"Sleep Med"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363624000636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363624000636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T21:59:43Z","timestamp":1738706383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363624000636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1262363624000636"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2024.101571","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparisons of the risks of new-onset prostate cancer in type 2 diabetes mellitus between SGLT2I and DPP4I users: A population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2024.101571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101571"}}